Combination treatment of r- tPA and an optimized human apyrase reduces mortality rate and hemorrhagic transformation 6h after ischemic stroke in aged female rats

Recombinant tissue plasminogen activator (r-tPA) is the only FDA-approved drug treatment for ischemic stroke and must be used within 4.5 hours. Thrombolytic treatment with r-tPA has deleterious effects on the neurovascular unit that substantially increases the risk of intracerebral hemorrhage if adm...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Tan, Zhenjun, Li, Xinlan, Turner, Ryan C, Logsdon, Aric F, Lucke-Wold, Brandon, DiPasquale, Kenneth, Jeong, Soon Soeg, Chen, Ridong, Huber, Jason D, Rosen, Charles L
Format: Artigo
Langue:Inglês
Publié: 2014
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4126582/
https://ncbi.nlm.nih.gov/pubmed/24933645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejphar.2014.05.052
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires